Surjit Pal, Pharma Analyst, Elara Capital, says that Ranbaxy will be able to grab market share of around 25-30 per cent for Lipitor brand. He added that Teva's entry as a partner for Lipitor was unexpected. At current levels, Ranbaxy shares are a 'Sell' with a target of Rs 350/share.
